Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Amagma is raising $2,275,888.00 in new funding. Sources indicate as part of senior management President, Tillman Gerngross played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Amagma
Amagma Therapeutics is a startup biotechnology company founded by proven serial entrepreneurs including Prof. Tillman Gerngross and Prof. Leonard Zon. Amagma scientists are working on the discovery and development of antibody therapeutics against inflammatory diseases (with a focus on GI disorders) which have proven intractable by other approaches. Amagma is based in Waltham, Massachusetts, and funded by private investors including Polaris Partners.

To learn more about Amagma, visit http://amagmatx.com/

Contact:
Tillman Gerngross, President
617-832-1000
tillman.gerngross@amagmatx.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved